Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05467748 · ClinicalTrials.gov registry record · Phase 1
EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer
A Phase 1 study of Non-Small Cell Lung Cancer, sponsored by VA Office of Research and Development.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
- 5
- Study locations
NCT05467748 is a Phase 1 study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 66 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (90% lower). The trial reports 5 study locations across 3 states.
The verdict
NCT05467748, a Phase 1 study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by VA Office of Research and Development.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is an open label, single arm, phase Ib/II clinical trial of checkpoint blockade, pembrolizumab and EZH2 inhibitor, tulmimetostat combination therapy for patients with advanced non-small cell lung cancer who have progressed from front or second-line treatment. Patients will be enrolled at multiple Veterans Affairs Medical Centers.
Conditions Studied
Interventions
- DRUG Tulmimetostat
Study Locations (5)
California
- VA Long Beach Healthcare System, Long Beach, CA - Long Beach
- VA Northern California Health Care System, Mather, CA - Sacramento
- VA San Diego Healthcare System, San Diego, CA - San Diego
Michigan
- VA Ann Arbor Healthcare System, Ann Arbor, MI - Ann Arbor
Texas
- Michael E. DeBakey VA Medical Center, Houston, TX - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2025-12-08 |
| Est. Completion | 2029-12-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05467748
The ClinicalTrials.gov registry entry for NCT05467748 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (90% lower). The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Tulmimetostat is the first listed.
NCT05467748 reports 5 study locations spanning 3 distinct geographic areas - top geographies include California, Michigan, Texas.
Frequently Asked Questions
What is clinical trial NCT05467748 about?
NCT05467748 is a clinical study titled "EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer". This is an open label, single arm, phase Ib/II clinical trial of checkpoint blockade, pembrolizumab and EZH2 inhibitor, tulmimetostat combination therapy for patients with advanced non-small cell lung cancer who have progressed from front or second-line treatment. Patients will be enrolled at multip...
What is the current status of trial NCT05467748?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2025-12-08. Estimated completion is 2029-12-07.
What conditions does trial NCT05467748 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT05467748?
The interventions under investigation include: Tulmimetostat (DRUG).
Who is sponsoring clinical trial NCT05467748?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05467748 being conducted?
This trial has 5 study locations across California, Michigan, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.